BioCentury
ARTICLE | Company News

Full Spectrum Genetics deal

May 20, 2013 7:00 AM UTC

Full Spectrum said it received a milestone payment from an undisclosed pharma under a 2012 deal to engineer and analyze variants of specified molecules using Full Spectrum's MapEng platform. The payment was triggered by the completion of the second of two projects generating multiple therapeutic protein and antibody candidates. The pharma has worldwide rights to products arising from the deal. Full Spectrum said it has received multiple payments and may be eligible for more. Earlier this month, the company announced the completion of the first project under the deal and the receipt of an associated milestone payment. The company declined to disclose details (see BioCentury, May 13). ...